QNCX has been in the news 563% more than usual
Nov 13, 2024, 9:31 PM
27.10%
What does QNCX do
Quince Therapeutics, based in South San Francisco, develops therapeutics using its AIDE technology to encapsulate drugs in patients' red blood cells, targeting rare diseases like Ataxia-Telangiectasia. The company went public on May 9, 2019, and employs 32 people.
QNCX has been in the news recently: Quince Therapeutics has enrolled 32 patients in its Phase 3 NEAT trial for Ataxia-Telangiectasia, with plans to complete enrollment by the second quarter of 2025. The company expects to report trial results in the fourth quarter of 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.